Allogeneic stem cell therapy allows "off the shelf" cells to be used in therapy, rather than having to take cells from each individual patient, allowing a relatively fast and inexpensive therapy.

Dr. Reisner is chair of the scientific advisory board for Cell Source and has equity in the company. These financial relationships have been disclosed to MD Anderson's Conflict of Interest Committee ...

In a new book, a science journalist recounts the story of a lifesaving treatment for infection that scientists broadly ...

This innovation brings the field closer to realizing off-the-shelf CAR-T therapies ... donor-derived CAR-T therapy and improve the accessibility of stem cell transplants and organ transplants.

The ability to suppress NK-mediated rejection is a key advancement in enabling off-the-shelf CAR-T therapy, supporting the potential to overcome scalability, logistics and cost challenges ...

or 'off-the-shelf,' CAR T-cell therapies. Unlike the traditional approach that requires extracting and modifying a patient's own cells (autologous therapy), allogeneic CAR T-cell therapy uses T ...

More than four years later—and after two rejections from the agency—Mesoblast has finally gained an endorsement from the U.S.

“As a [hypoimmune]-modified allogeneic CAR T therapy with a scaled manufacturing process that produces hundreds of patient ...

The TARVA bed frame looks humble, but this bed is actually winning all the popularity contests as one of IKEA’s bestsellers ...